首页 > 最新文献

International Journal of Alzheimer's Disease最新文献

英文 中文
Prognosis of Biomarker of Alzheimer's Disease in the Function of the Retina and Secondary Molecular Structure Variation of the Retina and Brain. 阿尔茨海默病生物标志物与视网膜功能的预后及视网膜和脑的二级分子结构变化。
Q1 Neuroscience Pub Date : 2023-01-01 DOI: 10.1155/2023/9775921
Heba Ahmed Gaber, Eman Mohamed Aly, Eman Saad Mohamed, Marwa Elfouly, Mona Salah Talaat, El-Sayed Mahmoud El-Sayed

Alzheimer's disease (AD) is one of the most serious neurodegenerative diseases in the globe. As a result, there is an acute need to discover indications that allow for early disease detection. There is growing scientific data showing the similarities between the eye and other central nervous system components, suggesting that information obtained in ophthalmic research might be valuable in the study and diagnosis of AD. Fifty male albino Wistar rats were separated into five groups: the first group served as control, and the other four groups of animals were administrated aluminium chloride (AlCl3) in a dose of 100 mg/kg body weight (b.w.) for 2, 4, 6, and 8 weeks, respectively. Insights into the function of the retina by electroretinogram (ERG) and the changes thought to have occurred in the molecular structure of the retina and brain using Fourier transform infrared spectroscopy (FTIR) as a result of AD progression induced by AlCl3 in rats were done. Moreover, the measurement of acetylcholinesterase (AchE) was done. After 6 and 8 weeks of AlCl3 injection, there was a substantial reduction (p ≤ 0.05) in a- and b-wave amplitudes and a significant rise (p ≤ 0.05) in implicit time compared to controls. A significant elevation (p ≤ 0.05) of AchE content was observed after 4, 6, and 8 weeks. FTIR revealed a significant increase (p ≤ 0.05) of β-turn and β-sheet content associated with significant decrease (p ≤ 0.05) of α-helix content for all groups administrated with AlCl3. Our findings suggest that retinal biomarkers such as ERG of the retina may be used as a screening tool for detection of AD. Secondary structural changes in the proteins of the retina and the brain were similar in AD rats' model and precede retinal dysfunction.

阿尔茨海默病(AD)是全球最严重的神经退行性疾病之一。因此,迫切需要发现能够早期发现疾病的指征。越来越多的科学数据显示,眼睛和其他中枢神经系统的组成部分存在相似之处,这表明在眼科研究中获得的信息可能对阿尔茨海默病的研究和诊断有价值。将50只雄性白化Wistar大鼠分为5组,第一组为对照组,其余4组分别给予100mg /kg体重的氯化铝(AlCl3)灌胃,灌胃时间为2、4、6、8周。通过视网膜电图(ERG)观察视网膜的功能,并利用傅立叶变换红外光谱(FTIR)分析AlCl3诱导大鼠AD进展导致的视网膜和大脑分子结构的变化。同时测定了乙酰胆碱酯酶(AchE)。注射AlCl3 6周和8周后,与对照组相比,a波和b波振幅显著降低(p≤0.05),隐式时间显著升高(p≤0.05)。4周、6周、8周时乙酰胆碱酯酶含量均显著升高(p≤0.05)。FTIR显示,AlCl3各组β-turn和β-sheet含量显著升高(p≤0.05),α-helix含量显著降低(p≤0.05)。我们的研究结果表明,视网膜生物标志物如视网膜ERG可能被用作检测AD的筛选工具。在AD大鼠模型中,视网膜和大脑蛋白质的继发性结构变化与视网膜功能障碍之前相似。
{"title":"Prognosis of Biomarker of Alzheimer's Disease in the Function of the Retina and Secondary Molecular Structure Variation of the Retina and Brain.","authors":"Heba Ahmed Gaber,&nbsp;Eman Mohamed Aly,&nbsp;Eman Saad Mohamed,&nbsp;Marwa Elfouly,&nbsp;Mona Salah Talaat,&nbsp;El-Sayed Mahmoud El-Sayed","doi":"10.1155/2023/9775921","DOIUrl":"https://doi.org/10.1155/2023/9775921","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is one of the most serious neurodegenerative diseases in the globe. As a result, there is an acute need to discover indications that allow for early disease detection. There is growing scientific data showing the similarities between the eye and other central nervous system components, suggesting that information obtained in ophthalmic research might be valuable in the study and diagnosis of AD. Fifty male albino Wistar rats were separated into five groups: the first group served as control, and the other four groups of animals were administrated aluminium chloride (AlCl<sub>3</sub>) in a dose of 100 mg/kg body weight (b.w.) for 2, 4, 6, and 8 weeks, respectively. Insights into the function of the retina by electroretinogram (ERG) and the changes thought to have occurred in the molecular structure of the retina and brain using Fourier transform infrared spectroscopy (FTIR) as a result of AD progression induced by AlCl<sub>3</sub> in rats were done. Moreover, the measurement of acetylcholinesterase (AchE) was done. After 6 and 8 weeks of AlCl<sub>3</sub> injection, there was a substantial reduction (<i>p</i> ≤ 0.05) in a- and b-wave amplitudes and a significant rise (<i>p</i> ≤ 0.05) in implicit time compared to controls. A significant elevation (<i>p</i> ≤ 0.05) of AchE content was observed after 4, 6, and 8 weeks. FTIR revealed a significant increase (<i>p</i> ≤ 0.05) of <i>β</i>-turn and <i>β</i>-sheet content associated with significant decrease (<i>p</i> ≤ 0.05) of <i>α</i>-helix content for all groups administrated with AlCl<sub>3</sub>. Our findings suggest that retinal biomarkers such as ERG of the retina may be used as a screening tool for detection of AD. Secondary structural changes in the proteins of the retina and the brain were similar in AD rats' model and precede retinal dysfunction.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2023 ","pages":"9775921"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9274080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia 多时间检测系统-寡聚淀粉样蛋白β (MDS-OAβ):一种基于血浆的生物标志物,可将阿尔茨海默病与其他病因的痴呆症区分
Q1 Neuroscience Pub Date : 2022-05-02 DOI: 10.1155/2022/9960832
J. Dominguez, Jeryl Yu, Ma Fe Payno De Guzman, E. Ampil, A. Guevarra, M. L. Joson, M. Reandelar, Ma. Socorro Martinez, Antonio D. Ligsay, Ferron Ocampo, Sangyun Kim
With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) is a noninvasive blood-based biomarker utilized to measure Aβ oligomerization tendency. We determined the difference in MDS-OAβ ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OAβ level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OAβ level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).
随着淀粉样蛋白治疗的出现,在进行淀粉样蛋白治疗之前,需要对患者的淀粉样蛋白状态进行记录,以确认临床诊断的病因。multi - timer Detection System-Oligomeric Amyloid-β (MDS-OAβ)是一种无创血液生物标志物,用于测量a β寡聚化趋势。我们确定了各组mds - oa - β比值的差异:(a)无认知障碍或主观认知障碍(NCI/SCI), (b)阿尔茨海默病(AD), (c)非AD, (d)混合性阿尔茨海默病-血管性痴呆(AD- vad)。AD和混合AD- vad患者的MDS-OAβ水平差异无统计学意义,但与NCI/SCI和非AD组相比,两者差异均有统计学意义。MDS-OAβ水平>1可能提示AD的临床变异或混合病理(AD- vad)。
{"title":"Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia","authors":"J. Dominguez, Jeryl Yu, Ma Fe Payno De Guzman, E. Ampil, A. Guevarra, M. L. Joson, M. Reandelar, Ma. Socorro Martinez, Antonio D. Ligsay, Ferron Ocampo, Sangyun Kim","doi":"10.1155/2022/9960832","DOIUrl":"https://doi.org/10.1155/2022/9960832","url":null,"abstract":"With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) is a noninvasive blood-based biomarker utilized to measure Aβ oligomerization tendency. We determined the difference in MDS-OAβ ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OAβ level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OAβ level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84798284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review. 阿杜单抗治疗阿尔茨海默病:叙述性综述。
Q1 Neuroscience Pub Date : 2022-03-09 eCollection Date: 2022-01-01 DOI: 10.1155/2022/9343514
Semira Abdi Beshir, A M Aadithsoorya, Affana Parveen, Sheron Sir Loon Goh, Nadia Hussain, Vineetha Bharathan Menon

Background: Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer's disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates.

Objective: In this narrative review, aducanumab approval-related controversy, the drug's pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized.

Methods: Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturer's website were searched.

Results: Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug.

Conclusion: Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.

背景:阿杜单抗是一种针对β-淀粉样蛋白聚集体的新型单克隆抗体,已获得美国食品及药物管理局的有条件批准,用于治疗轻度阿尔茨海默病(AD)。该药物在未证实对临床产生重大影响的情况下获得批准,引起了一些争论:在这篇叙述性综述中,总结了阿杜卡单抗获批的相关争议、该药的药代动力学和药效学特征、阿杜卡单抗的疗效和安全性试验证据、该药获批的影响以及治疗 AD 患者的未来方向:使用相关关键词搜索了谷歌学术、科学网、MEDLINE数据库和制造商网站:结果:高剂量输注阿杜单抗可适度减缓轻度认知障碍或早发性AD痴呆患者的认知能力下降。然而,这种药物会导致淀粉样蛋白相关成像异常。由于对认知能力的影响不大,AD 患者使用这种药物很可能会受到限制。生产商需要进行一项扩展的 IIIb 期试验,以验证这种药物的益处。接受治疗需要谨慎选择患者并进行定期监测,以确保药物的最佳使用效果:尽管存在种种局限,阿杜单抗仍是首个获准用于治疗AD的疾病修饰疗法。阿杜单抗只解决了 AD 发病机制的一部分,因此需要能作用于多个靶点的药物。此外,寻找有效、安全、方便、价格合理的预防策略、基于血浆的有效检测方法和更新的 AD 药物也至关重要。
{"title":"Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.","authors":"Semira Abdi Beshir, A M Aadithsoorya, Affana Parveen, Sheron Sir Loon Goh, Nadia Hussain, Vineetha Bharathan Menon","doi":"10.1155/2022/9343514","DOIUrl":"10.1155/2022/9343514","url":null,"abstract":"<p><strong>Background: </strong>Aducanumab, a new monoclonal antibody that targets <i>β</i>-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer's disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates.</p><p><strong>Objective: </strong>In this narrative review, aducanumab approval-related controversy, the drug's pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized.</p><p><strong>Methods: </strong>Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturer's website were searched.</p><p><strong>Results: </strong>Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug.</p><p><strong>Conclusion: </strong>Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":" ","pages":"9343514"},"PeriodicalIF":0.0,"publicationDate":"2022-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40307015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coresidence of Older Parents and Adult Children Increases Older Adults' Self-Reported Psychological Well-Being. 老年父母与成年子女同居增加老年人自我报告的心理健康。
Q1 Neuroscience Pub Date : 2022-01-27 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5406196
Soohyoung Rain Lee, Laurie S Kim

A multigenerational household is no longer a rare phenomenon in contemporary society. However, relevant literature has focused on elderly parents receiving support from their adult child, thereby coresiding. This is potentially problematic, as both generations could benefit from living together, and little is known about the benefit of living with adult children from older adults' perspectives compared to the risk of this living situation. Previous research suggests a significant negative effect of living alone, e.g., low psychological well-being, and it becomes more salient among single parents, such as widowed or divorced. The current paper utilizes the National Health Measurement Study with a sample of age 55 and over. Their SF-36 Mental Health and Physical Health Component and self-acceptance scores were measured. Path analysis reveals that both physical and mental health and self-acceptance scores are lower among single older adults at the time of the survey (e.g., divorced and widowed) than among those who are nonsingle and living with their adult child. A complete mediation effect of living with an adult child on older adults' mental health and self-acceptance was observed in both White and non-White minority older adults. This suggests that living with an adult child possibly serves as a protective factor for the negative relationship between living alone and their well-being. The current study seeks to stimulate ideas that might generate the following answer to community-based care in our contemporary aging society.

多代同堂在当代社会已不再是罕见的现象。然而,相关文献关注的是老年父母得到成年子女的支持,从而共同居住。这是一个潜在的问题,因为两代人都可以从生活在一起中受益,而且从老年人的角度来看,与这种生活状况的风险相比,与成年子女生活在一起的好处知之甚少。先前的研究表明,独居有显著的负面影响,例如心理健康状况不佳,而且在丧偶或离婚等单亲父母中表现得更为突出。目前的论文采用了国家健康测量研究,样本年龄在55岁及以上。测量他们的SF-36心理健康和身体健康成分以及自我接受得分。通径分析显示,在调查时,单身老年人(如离婚和丧偶)的身心健康和自我接受得分都低于非单身和与成年子女生活在一起的老年人。在白人和非白人少数民族老年人中,与成年子女一起生活对老年人的心理健康和自我接纳具有完全的中介效应。这表明,与成年子女生活在一起可能是一个保护因素,可以保护独居与他们的幸福感之间的负相关关系。目前的研究试图激发一些想法,这些想法可能会对我们当代老龄化社会中的社区护理产生以下答案。
{"title":"Coresidence of Older Parents and Adult Children Increases Older Adults' Self-Reported Psychological Well-Being.","authors":"Soohyoung Rain Lee,&nbsp;Laurie S Kim","doi":"10.1155/2022/5406196","DOIUrl":"https://doi.org/10.1155/2022/5406196","url":null,"abstract":"<p><p>A multigenerational household is no longer a rare phenomenon in contemporary society. However, relevant literature has focused on elderly parents receiving support from their adult child, thereby coresiding. This is potentially problematic, as both generations could benefit from living together, and little is known about the benefit of living with adult children from older adults' perspectives compared to the risk of this living situation. Previous research suggests a significant negative effect of living alone, e.g., low psychological well-being, and it becomes more salient among single parents, such as widowed or divorced. The current paper utilizes the National Health Measurement Study with a sample of age 55 and over. Their SF-36 Mental Health and Physical Health Component and self-acceptance scores were measured. Path analysis reveals that both physical and mental health and self-acceptance scores are lower among single older adults at the time of the survey (e.g., divorced and widowed) than among those who are nonsingle and living with their adult child. A complete mediation effect of living with an adult child on older adults' mental health and self-acceptance was observed in both White and non-White minority older adults. This suggests that living with an adult child possibly serves as a protective factor for the negative relationship between living alone and their well-being. The current study seeks to stimulate ideas that might generate the following answer to community-based care in our contemporary aging society.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2022 ","pages":"5406196"},"PeriodicalIF":0.0,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39894401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Validation of AD8-Philippines (AD8-P): A Brief Informant-Based Questionnaire for Dementia Screening in the Philippines. ad8 -菲律宾(AD8-P)的验证:一份简短的基于信息的菲律宾痴呆筛查问卷
Q1 Neuroscience Pub Date : 2021-10-31 eCollection Date: 2021-01-01 DOI: 10.1155/2021/7750235
Jacqueline C Dominguez, Ma Fe P de Guzman, Ma Lourdes C Joson, Krizelle Fowler, Boots P Natividad, Precy S Cruz, Jose Leo Jiloca, Primitivo B Mactal, Jayvee Dyne Dominguez, Jeffrey Domingo, Jhozel Kim Dominguez-Awao, Macario Reandelar, Jem R Javier, ThienKieuThi Phung, John C Morris, James E Galvin

Aim: This study was aimed at validating the Filipino version of AD8 (AD8-P).

Methods: Community-dwelling Filipino older persons aged ≥60 years, together with their informants, participated in this study. Psychologists independently interviewed the informants with AD8-P and administered the Filipino-validated Mini-Mental State Examination (MMSE-P) and Montreal Cognitive Assessment (MoCA-P) to the older persons. Neurologists and geriatrician conducted physical and neurological examination and Clinical Dementia Rating™ (CDR™) to determine cognitive diagnosis and were blinded with the results of AD8-P. Dementia was diagnosed based on DSM-IV-TR criteria. AD8-P discriminatory ability to screen for dementia was evaluated according to DSM-IV-TR diagnostic criteria for dementia.

Results: A total of 366 community-dwelling Filipino older persons aged ≥60 years, 213 with normal cognition and 153 with dementia, and their informants were included in this study. Majority (90%) were at the mildest stage of dementia. Area under the receiver-operating-characteristic curve (AUROC) for AD8-P was 0.94 (95% CI 0.92 to 0.96), demonstrating excellent overall predictive power to screen for dementia. The optimal AD8-P cut-off score with best balance sensitivity (91.5%) and specificity (77.9%) was ≥3.

Conclusion: AD8-P demonstrated good psychometric properties to screen for dementia, even at the earliest stage of cognitive decline.

目的:本研究旨在验证菲律宾版AD8 (AD8- p)。方法:社区居住的菲律宾≥60岁老年人及其举报人参与本研究。心理学家独立采访了AD8-P的举报者,并对老年人进行了菲律宾验证的迷你精神状态检查(MMSE-P)和蒙特利尔认知评估(MoCA-P)。神经学家和老年病专家进行了身体和神经学检查和临床痴呆评分™(CDR™)来确定认知诊断,并对AD8-P结果进行了盲测。痴呆的诊断依据DSM-IV-TR标准。根据DSM-IV-TR痴呆诊断标准评估AD8-P甄别痴呆的能力。结果:本研究共纳入366名年龄≥60岁的菲律宾社区老年人,213名认知正常,153名痴呆患者及其举报者。大多数(90%)处于痴呆的最轻阶段。AD8-P的受试者工作特征曲线下面积(AUROC)为0.94 (95% CI 0.92至0.96),显示出筛查痴呆的出色总体预测能力。最佳平衡敏感性(91.5%)和特异性(77.9%)的最佳AD8-P临界值≥3。结论:即使在认知能力下降的早期阶段,AD8-P也显示出良好的心理测量学特性。
{"title":"Validation of AD8-Philippines (AD8-P): A Brief Informant-Based Questionnaire for Dementia Screening in the Philippines.","authors":"Jacqueline C Dominguez, Ma Fe P de Guzman, Ma Lourdes C Joson, Krizelle Fowler, Boots P Natividad, Precy S Cruz, Jose Leo Jiloca, Primitivo B Mactal, Jayvee Dyne Dominguez, Jeffrey Domingo, Jhozel Kim Dominguez-Awao, Macario Reandelar, Jem R Javier, ThienKieuThi Phung, John C Morris, James E Galvin","doi":"10.1155/2021/7750235","DOIUrl":"10.1155/2021/7750235","url":null,"abstract":"<p><strong>Aim: </strong>This study was aimed at validating the Filipino version of AD8 (AD8-P).</p><p><strong>Methods: </strong>Community-dwelling Filipino older persons aged ≥60 years, together with their informants, participated in this study. Psychologists independently interviewed the informants with AD8-P and administered the Filipino-validated Mini-Mental State Examination (MMSE-P) and Montreal Cognitive Assessment (MoCA-P) to the older persons. Neurologists and geriatrician conducted physical and neurological examination and Clinical Dementia Rating™ (CDR™) to determine cognitive diagnosis and were blinded with the results of AD8-P. Dementia was diagnosed based on DSM-IV-TR criteria. AD8-P discriminatory ability to screen for dementia was evaluated according to DSM-IV-TR diagnostic criteria for dementia.</p><p><strong>Results: </strong>A total of 366 community-dwelling Filipino older persons aged ≥60 years, 213 with normal cognition and 153 with dementia, and their informants were included in this study. Majority (90%) were at the mildest stage of dementia. Area under the receiver-operating-characteristic curve (AUROC) for AD8-P was 0.94 (95% CI 0.92 to 0.96), demonstrating excellent overall predictive power to screen for dementia. The optimal AD8-P cut-off score with best balance sensitivity (91.5%) and specificity (77.9%) was ≥3.</p><p><strong>Conclusion: </strong>AD8-P demonstrated good psychometric properties to screen for dementia, even at the earliest stage of cognitive decline.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2021 ","pages":"7750235"},"PeriodicalIF":0.0,"publicationDate":"2021-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39711866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Genetic Research in Alzheimer Disease (GERALD) Initiative Finds rs9320913 as a Neural eQTL of lincRNA AL589740.1. 阿尔茨海默病基因研究 (GERALD) 计划发现 rs9320913 是 lincRNA AL589740.1 的神经 eQTL。
Q1 Neuroscience Pub Date : 2021-09-03 eCollection Date: 2021-01-01 DOI: 10.1155/2021/3064224
Lidia Lopez-Gutierrez, José María García-Alberca, Silvia Mendoza, Esther Gris, María Paz De la Guía, José Manuel Marin-Carmona, Emilio Alarcón-Martín, Almudena Lobato, Jose Manuel Cruz-Gamero, Laura Cura, Olga Ocejo, Javier Torrecilla, María Dolores Nieto, Concepción Urbano, Nuria Pareja, Macarena Luque, María García-Peralta, Rosario Carrillejo, José Luis Royo

Alzheimer's disease is the most common cause of dementia worldwide, and longitudinal studies are crucial to find the factors affecting disease development. Here, we describe a novel initiative from southern Spain designed to contribute in the identification of the genetic component of the cognitive decline of Alzheimer's disease patients. The germline variant rs9320913 is a C>A substitution mapping within a gene desert. Although it has been previously associated to a higher educational achievement and increased fluid intelligence, its role on Alzheimer's disease risk and progression remains elusive. A total of 407 subjects were included in the study, comprising 153 Alzheimer disease patients and 254 healthy controls. We have explored the rs9320913 contribution to both Alzheimer disease risk and progression according to the Mini-Mental State Exams. We found that rs9320913 maps within a central nervous system lincRNA AL589740.1. eQTL results show that rs9320913 correlated with the brain-frontal cortex (beta = -0.15, p value = 0.057) and brain-spinal cord (beta of -0.23, p value = 0.037). We did not find rs9320913 to be associated to AD risk, although AA patients seemed to exhibit a less pronounced Mini-Mental State Exam score decline.

阿尔茨海默病是全球最常见的痴呆症,纵向研究对于找到影响疾病发展的因素至关重要。在此,我们介绍了西班牙南部的一项新举措,旨在帮助确定阿尔茨海默病患者认知能力下降的遗传因素。种系变异 rs9320913 是基因沙漠中的一个 C>A 替换。尽管该基因变异与教育成就和流体智力的提高有关,但它对阿尔茨海默病风险和进展的作用仍难以捉摸。研究共纳入了 407 名受试者,其中包括 153 名阿尔茨海默病患者和 254 名健康对照者。我们根据迷你精神状态检查结果,探讨了 rs9320913 对阿尔茨海默病风险和进展的贡献。eQTL 结果显示,rs9320913 与脑-额叶皮层(β = -0.15,p 值 = 0.057)和脑-脊髓(β为 -0.23,p 值 = 0.037)相关。我们没有发现 rs9320913 与注意力缺失症风险有关,尽管 AA 患者似乎表现出较不明显的迷你精神状态检查评分下降。
{"title":"The Genetic Research in Alzheimer Disease (GERALD) Initiative Finds rs9320913 as a Neural eQTL of lincRNA AL589740.1.","authors":"Lidia Lopez-Gutierrez, José María García-Alberca, Silvia Mendoza, Esther Gris, María Paz De la Guía, José Manuel Marin-Carmona, Emilio Alarcón-Martín, Almudena Lobato, Jose Manuel Cruz-Gamero, Laura Cura, Olga Ocejo, Javier Torrecilla, María Dolores Nieto, Concepción Urbano, Nuria Pareja, Macarena Luque, María García-Peralta, Rosario Carrillejo, José Luis Royo","doi":"10.1155/2021/3064224","DOIUrl":"10.1155/2021/3064224","url":null,"abstract":"<p><p>Alzheimer's disease is the most common cause of dementia worldwide, and longitudinal studies are crucial to find the factors affecting disease development. Here, we describe a novel initiative from southern Spain designed to contribute in the identification of the genetic component of the cognitive decline of Alzheimer's disease patients. The germline variant rs9320913 is a C>A substitution mapping within a gene desert. Although it has been previously associated to a higher educational achievement and increased fluid intelligence, its role on Alzheimer's disease risk and progression remains elusive. A total of 407 subjects were included in the study, comprising 153 Alzheimer disease patients and 254 healthy controls. We have explored the rs9320913 contribution to both Alzheimer disease risk and progression according to the Mini-Mental State Exams. We found that rs9320913 maps within a central nervous system lincRNA AL589740.1. eQTL results show that rs9320913 correlated with the brain-frontal cortex (beta = -0.15, <i>p</i> value = 0.057) and brain-spinal cord (beta of -0.23, <i>p</i> value = 0.037). We did not find rs9320913 to be associated to AD risk, although AA patients seemed to exhibit a less pronounced Mini-Mental State Exam score decline.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2021 ","pages":"3064224"},"PeriodicalIF":0.0,"publicationDate":"2021-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39443832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modifying the Mini-Cog to Screen for Cognitive Impairment in Nonliterate Individuals. 修改Mini-Cog筛查非识字个体的认知障碍。
Q1 Neuroscience Pub Date : 2021-08-16 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5510093
Shambhu P Adhikari, Rubee Dev, Soo Borson

Objectives: The Mini-Cog, a rapid, valid, and reliable screening tool for cognitive impairment, consists of 3-word recall and an executive clock drawing test (CDT). However, CDT requires at least basic literacy and cultural exposure to analog clocks, conditions not met in many population groups around the world. We developed a modification of the Mini-Cog (MMC) for use with nonliterate and literate individuals.

Methods: Participants were adults (≥60 years) with no neurological diagnosis, with known cognitive impairment due to stroke, Parkinsonism, traumatic brain injury, or Alzheimer's disease, and whose family members were able to read and write. We replaced the CDT with two tasks of everyday life: a serial subtraction task or a multistep performance task. Family members rated the acceptability and feasibility of the Mini-Cog versions using a 6-point scale and completed a proxy-rated cognitive staging tool, the Dementia Severity Rating Scale (DSRS). Spearman's rho, Mann-Whitney U, and chi-square tests were used to evaluate group differences and associations between measures.

Results: Data were collected from 63 participants (75% ≥ 60 years, 67% nonliterate). Literacy was associated with CDT (chi-square strength 0.9, p < 0.001). Both MMC versions correlated with DSRS in healthy adults and patients (rho 0.6-0.7, p < 0.05). In literate individuals, the acceptability and feasibility of CDT and both alternate distractors were similarly high (5/6).

Conclusions: Two alternate distractor tasks may successfully replace CDT in the Mini-Cog. The MMC versions are promising and deserve further study as screening tools for cognitive impairment in larger and more fully characterized samples.

目的:Mini-Cog是一种快速、有效、可靠的认知障碍筛查工具,由三词回忆和执行时钟绘制测试(CDT)组成。然而,CDT至少需要基本的识字和对模拟时钟的文化了解,而世界上许多人口群体都不具备这些条件。我们开发了一个Mini-Cog (MMC)的修改,用于文盲和识字的个人。方法:参与者为成人(≥60岁),无神经学诊断,已知因中风、帕金森病、创伤性脑损伤或阿尔茨海默病引起的认知障碍,其家庭成员能够读写。我们用日常生活中的两个任务替换了CDT:一个连续减法任务或一个多步骤性能任务。家庭成员使用6分制量表对Mini-Cog版本的可接受性和可行性进行评分,并完成代理评定的认知分期工具,痴呆严重程度评定量表(DSRS)。使用Spearman’s rho、Mann-Whitney U和卡方检验来评估组间差异和测量之间的关联。结果:数据来自63名参与者(75%≥60岁,67%不识字)。读写能力与CDT相关(卡方强度0.9,p < 0.001)。两种MMC版本均与健康成人和患者的DSRS相关(rho 0.6-0.7, p < 0.05)。在有文化的个体中,CDT和两种备选分心物的可接受性和可行性同样高(5/6)。结论:两个交替的牵开器任务可以成功地替代Mini-Cog中的CDT。MMC版本很有前景,值得进一步研究,作为更大、更充分表征样本的认知障碍筛查工具。
{"title":"Modifying the Mini-Cog to Screen for Cognitive Impairment in Nonliterate Individuals.","authors":"Shambhu P Adhikari,&nbsp;Rubee Dev,&nbsp;Soo Borson","doi":"10.1155/2021/5510093","DOIUrl":"https://doi.org/10.1155/2021/5510093","url":null,"abstract":"<p><strong>Objectives: </strong>The Mini-Cog, a rapid, valid, and reliable screening tool for cognitive impairment, consists of 3-word recall and an executive clock drawing test (CDT). However, CDT requires at least basic literacy and cultural exposure to analog clocks, conditions not met in many population groups around the world. We developed a modification of the Mini-Cog (MMC) for use with nonliterate and literate individuals.</p><p><strong>Methods: </strong>Participants were adults (≥60 years) with no neurological diagnosis, with known cognitive impairment due to stroke, Parkinsonism, traumatic brain injury, or Alzheimer's disease, and whose family members were able to read and write. We replaced the CDT with two tasks of everyday life: a serial subtraction task or a multistep performance task. Family members rated the acceptability and feasibility of the Mini-Cog versions using a 6-point scale and completed a proxy-rated cognitive staging tool, the Dementia Severity Rating Scale (DSRS). Spearman's rho, Mann-Whitney <i>U</i>, and chi-square tests were used to evaluate group differences and associations between measures.</p><p><strong>Results: </strong>Data were collected from 63 participants (75% ≥ 60 years, 67% nonliterate). Literacy was associated with CDT (chi-square strength 0.9, <i>p</i> < 0.001). Both MMC versions correlated with DSRS in healthy adults and patients (rho 0.6-0.7, <i>p</i> < 0.05). In literate individuals, the acceptability and feasibility of CDT and both alternate distractors were similarly high (5/6).</p><p><strong>Conclusions: </strong>Two alternate distractor tasks may successfully replace CDT in the Mini-Cog. The MMC versions are promising and deserve further study as screening tools for cognitive impairment in larger and more fully characterized samples.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2021 ","pages":"5510093"},"PeriodicalIF":0.0,"publicationDate":"2021-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39356310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Improving the Quality of Life of Family Caregivers of People with Alzheimer's Disease through Virtual Communities of Practice: A Quasiexperimental Study. 通过虚拟实践社区改善阿尔茨海默病患者家庭照护者的生活质量:一项准实验研究
Q1 Neuroscience Pub Date : 2021-04-05 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8817491
Montse Romero-Mas, Anna Ramon-Aribau, Dyego Leandro Bezerra de Souza, Andrew M Cox, Beni Gómez-Zúñiga

Caring for a person with dementia burdens family caregivers, and there is a close negative relationship between this burden and their quality of life (QoL). Research suggests that caregivers' main needs are information and training about the disease and support from others experiencing the same situation, and Internet interventions hold considerable promise for meeting these needs. Virtual communities of practice (VCoPs) are Internet frameworks to share knowledge where members collaborate and achieve a sense of trust in the community. This paper seeks to evaluate the impact of participating in a VCoP (developed through an App) on the QoL of caregivers to people with Alzheimer's. Results show QoL before and after the intervention changed significantly. The impact of VCoP on caregivers' overall QoL is moderated by age and relation with the person with Alzheimer's, specifically those over 65, and spouses. VCoPs allow interaction and knowledge sharing among caregivers which provide them mainly with information and support from peers helping them to meet their needs. Furthermore, caregivers' QoL did not decrease when their relative deteriorated functionally, which could be due to the participation in VCoP. Although we found significant pre- and post differences in caregivers' health literacy, we must report the ambiguous result that this variable only impacts on QoL's physical domain. Participants also reported that they had a positive experience because the App was perceived to be a useful tool, because they could manage their own participation and they met peers and felt less lonely. Results suggest that participation in a VCoP impacts positively on caregivers' QoL.

照顾痴呆症患者给家庭照顾者带来负担,这种负担与他们的生活质量(QoL)之间存在密切的负相关关系。研究表明,护理人员的主要需求是有关疾病的信息和培训,以及来自其他有相同情况的人的支持,而互联网干预措施在满足这些需求方面具有很大的希望。虚拟实践社区(vcop)是一种互联网框架,用于共享知识,成员可以在其中协作并在社区中实现信任感。本文旨在评估参与VCoP(通过App开发)对阿尔茨海默病患者护理人员生活质量的影响。结果:干预前后生活质量变化明显。VCoP对照顾者总体生活质量的影响受年龄和与阿尔茨海默病患者(特别是65岁以上的人)的关系以及配偶的影响。vcop允许护理人员之间的互动和知识共享,主要为他们提供来自同伴的信息和支持,帮助他们满足自己的需求。此外,当他们的相对功能恶化时,照顾者的生活质量并没有下降,这可能是由于参与了VCoP。尽管我们发现护理人员健康素养前后存在显著差异,但我们必须报告这一模糊结果,即该变量仅影响生活质量的物理领域。参与者还报告说,他们有一个积极的体验,因为应用程序被认为是一个有用的工具,因为他们可以管理自己的参与,他们遇到了同龄人,感觉不那么孤独。结果表明,参加VCoP对照顾者的生活质量有积极的影响。
{"title":"Improving the Quality of Life of Family Caregivers of People with Alzheimer's Disease through Virtual Communities of Practice: A Quasiexperimental Study.","authors":"Montse Romero-Mas, Anna Ramon-Aribau, Dyego Leandro Bezerra de Souza, Andrew M Cox, Beni Gómez-Zúñiga","doi":"10.1155/2021/8817491","DOIUrl":"10.1155/2021/8817491","url":null,"abstract":"<p><p>Caring for a person with dementia burdens family caregivers, and there is a close negative relationship between this burden and their quality of life (QoL). Research suggests that caregivers' main needs are information and training about the disease and support from others experiencing the same situation, and Internet interventions hold considerable promise for meeting these needs. Virtual communities of practice (VCoPs) are Internet frameworks to share knowledge where members collaborate and achieve a sense of trust in the community. This paper seeks to evaluate the impact of participating in a VCoP (developed through an App) on the QoL of caregivers to people with Alzheimer's. Results show QoL before and after the intervention changed significantly. The impact of VCoP on caregivers' overall QoL is moderated by age and relation with the person with Alzheimer's, specifically those over 65, and spouses. VCoPs allow interaction and knowledge sharing among caregivers which provide them mainly with information and support from peers helping them to meet their needs. Furthermore, caregivers' QoL did not decrease when their relative deteriorated functionally, which could be due to the participation in VCoP. Although we found significant pre- and post differences in caregivers' health literacy, we must report the ambiguous result that this variable only impacts on QoL's physical domain. Participants also reported that they had a positive experience because the App was perceived to be a useful tool, because they could manage their own participation and they met peers and felt less lonely. Results suggest that participation in a VCoP impacts positively on caregivers' QoL.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2021 ","pages":"8817491"},"PeriodicalIF":0.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38897104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Current State of Non-wearable Sensor Technologies for Monitoring Activity Patterns to Detect Symptoms of Mild Cognitive Impairment to Alzheimer's Disease. 用于监测活动模式以检测阿尔茨海默病轻度认知障碍症状的非穿戴式传感器技术的现状。
Q1 Neuroscience Pub Date : 2021-02-10 eCollection Date: 2021-01-01 DOI: 10.1155/2021/2679398
Rajaram Narasimhan, Muthukumaran G, Charles McGlade

Mild cognitive impairment (MCI) could be a transitory stage to Alzheimer's disease (AD) and underlines the importance of early detection of this stage. In MCI stage, though the older adults are not completely dependent on others for day-to-day tasks, mild impairments are seen in memory, attention, etc., subtly affecting their daily activities/routines. Smart sensing technologies, such as wearable and non-wearable sensors, coupled with advanced predictive modeling techniques enable daily activities/routines based early detection of MCI symptoms. Non-wearable sensors are less intrusive and can monitor activities at naturalistic environment with no interference to an individual's daily routines. This review seeks to answer the following questions: (1) What is the evidence for use of non-wearable sensor technologies in early detection of MCI/AD utilizing daily activity data in an unobtrusive manner? (2) How are the machine learning methods being employed in analyzing activity data in this early detection approach? A systematic search was conducted in databases such as IEEE Explorer, PubMed, Science Direct, and Google Scholar for the papers published from inception till March 2019. All studies that fulfilled the following criteria were examined: a research goal of detecting/predicting MCI/AD, daily activities data to detect MCI/AD, noninvasive/non-wearable sensors for monitoring activity patterns, and machine learning techniques to create the prediction models. Out of 2165 papers retrieved, 12 papers were eligible for inclusion in this review. This review found a diverse selection of aspects such as sensors, activity domains/features, activity recognition methods, and abnormality detection methods. There is no conclusive evidence on superiority of one or more of these aspects over the others, especially on the activity feature that would be the best indicator of cognitive decline. Though all these studies demonstrate technological developments in this field, they all suggest it is far in the future it becomes an effective diagnostic tool in real-life clinical practice.

轻度认知障碍(MCI)可能是阿尔茨海默病(AD)的一个过渡阶段,并强调了早期发现这一阶段的重要性。在轻度认知障碍阶段,虽然老年人在日常生活中并不完全依赖他人,但在记忆、注意力等方面出现了轻微的损伤,潜移默化地影响了他们的日常活动。智能传感技术,如可穿戴和非可穿戴传感器,加上先进的预测建模技术,能够基于日常活动/常规早期发现轻度认知障碍症状。非穿戴式传感器的侵入性较小,可以在不干扰个人日常生活的情况下监测自然环境中的活动。本综述旨在回答以下问题:(1)使用非可穿戴传感器技术以不引人注目的方式利用日常活动数据进行MCI/AD的早期检测的证据是什么?(2)在这种早期检测方法中,机器学习方法如何用于分析活动数据?在IEEE Explorer、PubMed、Science Direct和Google Scholar等数据库中系统检索了从成立到2019年3月发表的论文。所有符合以下标准的研究都进行了检查:检测/预测MCI/AD的研究目标,检测MCI/AD的日常活动数据,监测活动模式的非侵入性/非穿戴式传感器,以及创建预测模型的机器学习技术。在检索到的2165篇论文中,有12篇论文符合纳入本综述的条件。这篇综述发现了传感器、活动域/特征、活动识别方法和异常检测方法等方面的不同选择。没有确凿的证据表明其中一个或多个方面比其他方面更优越,特别是在活动特征上,这是认知能力下降的最佳指标。尽管所有这些研究都展示了该领域的技术发展,但它们都表明,在未来,它将成为现实生活中临床实践的有效诊断工具。
{"title":"Current State of Non-wearable Sensor Technologies for Monitoring Activity Patterns to Detect Symptoms of Mild Cognitive Impairment to Alzheimer's Disease.","authors":"Rajaram Narasimhan,&nbsp;Muthukumaran G,&nbsp;Charles McGlade","doi":"10.1155/2021/2679398","DOIUrl":"https://doi.org/10.1155/2021/2679398","url":null,"abstract":"<p><p>Mild cognitive impairment (MCI) could be a transitory stage to Alzheimer's disease (AD) and underlines the importance of early detection of this stage. In MCI stage, though the older adults are not completely dependent on others for day-to-day tasks, mild impairments are seen in memory, attention, etc., subtly affecting their daily activities/routines. Smart sensing technologies, such as wearable and non-wearable sensors, coupled with advanced predictive modeling techniques enable daily activities/routines based early detection of MCI symptoms. Non-wearable sensors are less intrusive and can monitor activities at naturalistic environment with no interference to an individual's daily routines. This review seeks to answer the following questions: (1) What is the evidence for use of non-wearable sensor technologies in early detection of MCI/AD utilizing daily activity data in an unobtrusive manner? (2) How are the machine learning methods being employed in analyzing activity data in this early detection approach? A systematic search was conducted in databases such as IEEE Explorer, PubMed, Science Direct, and Google Scholar for the papers published from inception till March 2019. All studies that fulfilled the following criteria were examined: a research goal of detecting/predicting MCI/AD, daily activities data to detect MCI/AD, noninvasive/non-wearable sensors for monitoring activity patterns, and machine learning techniques to create the prediction models. Out of 2165 papers retrieved, 12 papers were eligible for inclusion in this review. This review found a diverse selection of aspects such as sensors, activity domains/features, activity recognition methods, and abnormality detection methods. There is no conclusive evidence on superiority of one or more of these aspects over the others, especially on the activity feature that would be the best indicator of cognitive decline. Though all these studies demonstrate technological developments in this field, they all suggest it is far in the future it becomes an effective diagnostic tool in real-life clinical practice.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2021 ","pages":"2679398"},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25402866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Structural Brain Imaging Phenotypes of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) Found by Hierarchical Clustering. 通过层次聚类发现轻度认知功能障碍(MCI)和阿尔茨海默病(AD)的脑结构成像表型
Q1 Neuroscience Pub Date : 2020-11-13 eCollection Date: 2020-01-01 DOI: 10.1155/2020/2142854
Mikko Kärkkäinen, Mithilesh Prakash, Marzieh Zare, Jussi Tohka, For The Alzheimer's Disease Neuroimaging Initiative

A hierarchical clustering algorithm was applied to magnetic resonance images (MRI) of a cohort of 751 subjects having a mild cognitive impairment (MCI), 282 subjects having received Alzheimer's disease (AD) diagnosis, and 428 normal controls (NC). MRIs were preprocessed to gray matter density maps and registered to a stereotactic space. By first rendering the gray matter density maps comparable by regressing out age, gender, and years of education, and then performing the hierarchical clustering, we found clusters displaying structural features of typical AD, cortically-driven atypical AD, limbic-predominant AD, and early-onset AD (EOAD). Among these clusters, EOAD subjects displayed marked cortical gray matter atrophy and atrophy of the precuneus. Furthermore, EOAD subjects had the highest progression rates as measured with ADAS slopes during the longitudinal follow-up of 36 months. Striking heterogeneities in brain atrophy patterns were observed with MCI subjects. We found clusters of stable MCI, clusters of diffuse brain atrophy with fast progression, and MCI subjects displaying similar atrophy patterns as the typical or atypical AD subjects. Bidirectional differences in structural phenotypes were found with MCI subjects involving the anterior cerebellum and the frontal cortex. The diversity of the MCI subjects suggests that the structural phenotypes of MCI subjects would deserve a more detailed investigation with a significantly larger cohort. Our results demonstrate that the hierarchical agglomerative clustering method is an efficient tool in dividing a cohort of subjects with gray matter atrophy into coherent clusters manifesting different structural phenotypes.

对 751 名轻度认知障碍(MCI)受试者、282 名阿尔茨海默病(AD)诊断受试者和 428 名正常对照组(NC)的磁共振图像(MRI)采用了分层聚类算法。核磁共振成像经过预处理后生成灰质密度图,并注册到立体定向空间。首先通过回归年龄、性别和教育年限使灰质密度图具有可比性,然后进行分层聚类,我们发现了具有典型AD、皮质驱动的非典型AD、边缘主导型AD和早发AD(EOAD)结构特征的聚类。在这些群组中,EOAD受试者表现出明显的皮质灰质萎缩和楔前肌萎缩。此外,在36个月的纵向随访中,以ADAS斜率衡量,EOAD受试者的病情恶化率最高。MCI受试者的脑萎缩模式存在显著的异质性。我们发现了稳定型MCI群、进展迅速的弥漫性脑萎缩群以及与典型或非典型AD受试者表现出相似萎缩模式的MCI受试者。MCI受试者的结构表型存在双向差异,涉及小脑前部和额叶皮层。MCI受试者的多样性表明,MCI受试者的结构表型值得在更大的群体中进行更详细的研究。我们的研究结果表明,分层聚类方法是将灰质萎缩受试者分为表现出不同结构表型的连贯群组的有效工具。
{"title":"Structural Brain Imaging Phenotypes of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) Found by Hierarchical Clustering.","authors":"Mikko Kärkkäinen, Mithilesh Prakash, Marzieh Zare, Jussi Tohka, For The Alzheimer's Disease Neuroimaging Initiative","doi":"10.1155/2020/2142854","DOIUrl":"10.1155/2020/2142854","url":null,"abstract":"<p><p>A hierarchical clustering algorithm was applied to magnetic resonance images (MRI) of a cohort of 751 subjects having a mild cognitive impairment (MCI), 282 subjects having received Alzheimer's disease (AD) diagnosis, and 428 normal controls (NC). MRIs were preprocessed to gray matter density maps and registered to a stereotactic space. By first rendering the gray matter density maps comparable by regressing out age, gender, and years of education, and then performing the hierarchical clustering, we found clusters displaying structural features of typical AD, cortically-driven atypical AD, limbic-predominant AD, and early-onset AD (EOAD). Among these clusters, EOAD subjects displayed marked cortical gray matter atrophy and atrophy of the precuneus. Furthermore, EOAD subjects had the highest progression rates as measured with ADAS slopes during the longitudinal follow-up of 36 months. Striking heterogeneities in brain atrophy patterns were observed with MCI subjects. We found clusters of stable MCI, clusters of diffuse brain atrophy with fast progression, and MCI subjects displaying similar atrophy patterns as the typical or atypical AD subjects. Bidirectional differences in structural phenotypes were found with MCI subjects involving the anterior cerebellum and the frontal cortex. The diversity of the MCI subjects suggests that the structural phenotypes of MCI subjects would deserve a more detailed investigation with a significantly larger cohort. Our results demonstrate that the hierarchical agglomerative clustering method is an efficient tool in dividing a cohort of subjects with gray matter atrophy into coherent clusters manifesting different structural phenotypes.</p>","PeriodicalId":13802,"journal":{"name":"International Journal of Alzheimer's Disease","volume":"2020 ","pages":"2142854"},"PeriodicalIF":0.0,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38705801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Alzheimer's Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1